Drug
Enoblituzumab
Enoblituzumab: highest development phase Phase 2/3, developed by MacroGenics. 5 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- MacroGenics
Trials
| Drug | Phase | Indication |
|---|---|---|
| enoblituzumab NCT04129320 | Phase 2/3 | Head and Neck Cancer |
| Enoblituzumab NCT04634825 | Phase 2 | Head and Neck Cancer |
| Enoblituzumab NCT02923180 | Phase 2 | Prostate Cancer |
| Enoblituzumab NCT06014255 | Phase 2 | Prostate Cancer |
| Enoblituzumab NCT02982941 | Phase 1 | Neuroblastoma |
Latest
No recent events.
Follow Enoblituzumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.